Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick R Appelbaum

Showing results (261-270 of 339) with videos related to

Pageof 34
Sort By:
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantationMohamed L Sorror, Rainer F Storb, Brenda M Sandmaier, et al.
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Blood|July 7, 2012
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDSH Joachim Deeg, Bart L Scott, Min Fang, et al.
Blood|April 20, 2002
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphomaAjay K Gopal, Joseph G Rajendran, Stephen H Petersdorf, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Blood|November 11, 2006
End points to establish the efficacy of new agents in the treatment of acute leukemiaFrederick R Appelbaum, Daniel Rosenblum, Robert J Arceci, et al.
Annals of Internal Medicine|January 21, 2020
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 CohortsGeorge B McDonald, Brenda M Sandmaier, Marco Mielcarek, et al.
Bone Marrow Transplantation|September 27, 2020
Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approachMasumi Ueda Oshima, Brenda M Sandmaier, Effie Petersdorf, et al.
British Journal of Haematology|April 23, 2014
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical designJack M Lionberger, John M Pagel, Vicky K Sandhu, et al.
Pageof 34

Showing results (261-270 of 339) with videos related to

Sort By:
Pageof 34
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantationMohamed L Sorror, Rainer F Storb, Brenda M Sandmaier, et al.
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Blood|July 7, 2012
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDSH Joachim Deeg, Bart L Scott, Min Fang, et al.
Blood|April 20, 2002
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphomaAjay K Gopal, Joseph G Rajendran, Stephen H Petersdorf, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Blood|November 11, 2006
End points to establish the efficacy of new agents in the treatment of acute leukemiaFrederick R Appelbaum, Daniel Rosenblum, Robert J Arceci, et al.
Annals of Internal Medicine|January 21, 2020
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 CohortsGeorge B McDonald, Brenda M Sandmaier, Marco Mielcarek, et al.
Bone Marrow Transplantation|September 27, 2020
Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approachMasumi Ueda Oshima, Brenda M Sandmaier, Effie Petersdorf, et al.
British Journal of Haematology|April 23, 2014
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical designJack M Lionberger, John M Pagel, Vicky K Sandhu, et al.
Pageof 34